Zane Yang

Company: ABM Therapeutics

Job title: Chief Medical Officer

Seminars:

Targeting MAPK Signalling Pathways to Stop GBM Tumor Cell Proliferation 12:00 pm

Introducing a new generation of brain penetrant BRAF inhibitors for GBM ABM-1310 for BRAF v600-mutant GBM tumors- Phase I study Clinical evidence of ABM-1310 in high grade gliomas including GBMRead more

day: Conference Day 2